Ornithine transcarbamylase (OTC) deficiency is an X-linked recessive disorder that usually presents in the neonatal period. Late-onset presentation of OTC can cause mild to severe symptoms. We describe laboratory and clinical findings of late-onset presentations of OTC deficiency. We conducted a literature search using search terms "ornithine transcarbamylase deficiency," "late onset presentation," and "hyperammonemia" from January 1, 1987, to December 31, 2016, was performed. Only papers published in English were included. We searched on PubMed, MEDLINE, and Google Scholar. We also present 2 OTC deficiency cases. A total of 30 adult cases had late-onset presentation of OTC deficiency reported. The majority were women (57%) with a median age of 37 years. The median level of ammonia was 308 mmol/L and the mortality rate was 30%. Our case 1 was a 40-year-old woman who succumbed to neurologic complications after a hyperammonemia crisis following an increased protein intake. Our case 2 was a 43-year-old woman with seizures associated with increased ammonia levels. Our 2 case reports show the wide phenotypic variability and severity in late-onset presentation of OTC ranging from seizures to cerebral herniation. Our literature review is the first to detail published laboratory and neurologic sequelae of late-onset OTC deficiency.
Introduction
Ammonia is predominantly produced by skeletal muscle by deamination of adenosine monophosphate from amino acid catabolism, and from absorption from the gut. 1 Ammonia is taken up by hepatocytes, metabolized in the urea cycle, and excreted ( Figure 1 ). A number of inherited enzymatic defects in the urea cycle ultimately result in an increase in ammonia. The rate limiting step in the urea cycle is by carbamoyl phosphate synthase. The product of this reaction, carbamoyl phosphate, reacts with ornithine transcarbamylase (OTC) to transfer a carbamoyl group to ornithine producing citrulline. This reaction mediated by OTC occurs in the mitochondria of liver cells. Carbamoyl phosphate is produced in excess during OTC deficiency, with some of this product reacting with aspartate to generate orotic acid, which is subsequently excreted in the urine. Interruption of this biochemical pathway results in elevated ammonia. Therefore, patients with OTC deficiency present with elevated ammonia, orotic aciduria, and low plasma citrulline. 2 Hyperammonemia may lead to a variety of cerebral dysfunctions including encephalopathy, seizures, cerebral edema, intracranial hypertension, coma, and death.
Materials and Methods
We conducted a literature review of all the adult cases of late-onset presentation of OTC deficiency from January 1, 1987 , to December 31, 2016. We searched on PubMed/ National Library of Medicine, MEDLINE, and Google Scholar using the terms "ornithine transcarbamylase deficiency," "late-onset presentation," and "hyperammonemia crisis." Only papers published in English that reported age at onset of symptoms, sex of patient, ammonia levels, clinical manifestations, proposed reason for clinical decompensation, and whether the patient survived their hyperammonemia crisis were included. We also present 2 OTC deficiency cases, 1 from each of our academic institutions. The case reports were obtained by chart review of our patients, which included all clinical notes, laboratory testing, imaging, outside records, and outpatient evaluations.
Results
Using the search term "ornithine transcarbamylase deficiency" yielded 1084 PubMed/National Library of Medicine publications. When combined with "late onset presentation" this yielded only 20 results, and when "hyperammonemia crisis" was added, this yielded only 1 result. Among all the search combinations and sources, a total of 171 publications results were found. We then excluded 145 papers that did not meet the inclusion criteria, leaving 26 papers, which contained a total of 30 patients. This revealed a precision of only 171/1084 (16%) and sensitivity of 26/171 (15%), but is likely indicative of the larger body of pediatric OTC deficiency or other results. Therefore, of the initial 171 papers reviewed, only 26 papers that best matched the adultonset or late-onset presentation of this condition appear to be very uncommon, especially when one considers a late-onset hyperammonemia crisis.
We reviewed 10 published cases of women with OTC deficiency presenting with first-time seizure as their initial symptomatic presentation. The mean urine orotic acid level was 143 mmol/mol creatinine and mean serum ammonia was 294 mmol/L. In our search of all 30 reported cases of adultonset presentation of OTC deficiency, the median age at presentation was 37 years (range: 13-67). Just over half of the patients were women (17 [57%] ), the median level of ammonia was 308 mmol/L, and (when reported in only 15 cases) the median urine orotic acid was 114 mmol/mol creatinine. Thirteen (43%) of 30 patients had a hyperammonemia crisis after a change in diet with increased protein intake. The most common clinical presentations were mental status changes, seizures, cerebral edema, and death. The overall mortality rate was 30% (Table 1) .
3-28

Case 1
A 40-year-old woman with a past medical history of OTC deficiency, migraine headaches, asthma, and hypertension presented to an outside facility with altered mental status. Her family history included the deaths of 2 newborn sons due to OTC complications. The family had celebrated Thanksgiving 3 days prior to admission, during which the patient had a large meal of turkey, representing a substantial protein load. Shortly after, the patient experienced generalized fatigue, anorexia, nausea, and confusion. On the day of admission to the outside facility, the patient suffered multiple seizures at home. At the hospital, the patient had a Glasgow Coma Scale score of 3 and was in status epilepticus. Lorazepam and levetiracetam were administered, and endotracheal intubation for airway protection was performed. Initial laboratory testing showed ammonia levels over 400 mmol/L, and computed tomography of the head was negative for acute pathologies. Arginine was administered, and intermittent hemodialysis therapy was started. The patient remained hospitalized for 3 days with no neurologic improvement. The patient's serum ammonia increased to 848 mmol/L. On hospital day 4, the patient continued to have increasing levels of ammonia and no clinical improvement and was subsequently transferred to our facility.
Physical examination upon arrival to our neuroscience intensive care unit (NICU) revealed pupils that were 4 mm bilateral and nonreactive to light; corneal and oculocephalic reflexes were also absent. Initial laboratory results showed a white blood cell count of 8.2 Â 10 9 /L, hemoglobin 9.3 g/dL, sodium 169 mmol/L, calcium 7.6 mg/dL, and normal potassium and glucose. Liver enzymes were within normal values, and serum ammonia was 553 mmol/L. No citrulline or orotic acid levels were measured. A transcranial Doppler showed reversal of blood flow, and a pulsatility index of 1.82 and resistivity index of 0.90 in the proximal area of the right middle cerebral arteries, indicating poor intracranial compliance. A computed tomography angiogram of the head demonstrated global intracranial cytotoxic edema with obliteration of (Figure 2 ). Therapeutic hypothermia was initiated due to concern for intracranial hypertension. An electroencephalogram (EEG) recording demonstrated no discernible activity from either hemisphere at a setting of 7 mV and minimal y frequencies from the left posterior temporal region and right frontocentral region at a setting of 2 mV. A single dose of desmopressin 0.5 mg was administered to lower sodium levels. An infusion of arginine at 75.2 mL/h was administered, and sodium benzoate and sodium phenylbutyrate were initiated to help metabolize ammonia. Emergent continuous renal replacement therapy was initiated and ammonia levels dropped to 173 mmol/L although there was no change in neurologic status. After 24 hours of hypothermia, the patient was rewarmed to 37 C at a rate of 0.25 C/h. After the patient achieved normothermia and the sedating medications wore off, neurologic examination revealed brain death. The family was informed and subsequently decided to withdraw care.
Case 2
A 43-year-old woman with past medical history of bipolar disorder and migraine headaches, and a family history of a son who died at 22 months of age due to OTC deficiency was admitted to the hospital due to seizures. Her father witnessed the seizure, which he described as jerking movements of the arms and legs with bladder incontinence. Laboratory testing consisting of a complete blood count, basic metabolic panel, and urinalysis at admission showed no abnormalities, but no ammonia level was obtained. Magnetic resonance imaging of the brain was negative for any structural abnormalities. No apparent cause was found for the seizure activity. The patient was started on oxcarbazepine 600 mg, and her prior medication of topiramate 50 mg twice a day for her migraine headaches was continued. The patient was discharged on the second day of admission with follow-up with neurology.
The patient underwent an elective foraminotomy of the right L4-5 vertebrae 8 months later. She developed agitation and confusion on postoperative day 2, and oxcarbazepine was decreased to 300 mg twice a day. On postoperative day 4, the patient developed a pulmonary embolism and was transferred to the NICU. The patient's mental status showed no improvement, and ammonia levels were 130 mmol/L. She was started on lactulose for hyperammonemia and sodium valproate for seizure prophylaxis. Her ammonia levels increased to 203 mmol/L the next day. Suspicion for a metabolic disorder was raised and urine orotic acid levels were highly elevated, which was consistent with a female carrier of OTC deficiency. Sodium valproate was discontinued and ammonia levels dropped to 45 mmol/L. The patient's mental status improved, and she was later discharged home on oxcarbazepine 300 mg twice a day and lactulose.
Literature Review
Genetics and phenotypic variability. Ornithine transcarbamylase deficiency is the most common inherited defect of the urea cycle. Expression of the OTC gene occurs in the liver and small intestine, but the complete urea cycle expression and activity only occur in the liver. Over 400 disease-causing mutations have been identified. 29 Diagnosis of OTC deficiency based on DNA testing is by sequencing OTC exons and intron/exon boundaries. These methods confirm OTC deficiency in 80% to 90% of clinically suspected patients. 30 Novel de novo mutations continue to be described with 29 new mutations recently identified. 29 Diagnostically, elevated urine orotic acid ( Figure  1 ) in the setting of elevated serum ammonia and alanine has a sensitivity of 91% and specificity of 70%. 31 Heterozygous females can demonstrate various phenotypes based on lyonization in the liver. 32, 33 Even among related female patients there can be phenotypic differences. In a study of 2 biological sisters with a genetic diagnosis of OTC mutation, 1 sister has been symptomatic since 8 years of age while the other has remained asymptomatic through 28 years of age. 17 In the late-onset presentation of OTC, patients can have encephalopathic episodes after a precipitant event such as change in diet, acute illness, trauma, pregnancy, and use of corticosteroids or valproic acid. 34, 35 Heterozygous female patients may self-select a low-protein diet due to gastrointestinal symptoms associated with high-protein meals. 9 One pound of turkey can have around 127 to 133 g of protein, which exceeds the maximum amount of protein recommended in OTC patients (generally around 0.8 g/kg/d). 36 Treatment of OTC deficiency. The mainstay treatment of acute hyperammonemia due to OTC deficiency is restriction of dietary protein, arginine, or citrulline supplementation; high caloric support to promote an anabolic state (with insulin supplementation as needed); and the promotion of alternative pathways to divert amino acid nitrogen away from the urea cycle with nitrogen-scavenging medication. 37 The initial approach in treating hyperammonemia is to stop all protein intake for at least 24 to 48 hours, restart intake at 0.25 to 0.5 g/kg, and then titrate up. Sodium benzoate and phenylbutyrate utilize alternative pathways to divert amino acid nitrogen away from the urea cycle. Approximately 40% of benzoate conjugates with glycine and is converted to hippuric acid and 50% to 90% of phenylbutyrate conjugates with glutamine and forms phenylacetylglutamine, which is excreted in the urine. 1, 38 Intravenous sodium benzoate and sodium phenylacetate have proven to increase survival rates in patients with hyperammonemia crisis. 39 Patients weighing more than 25 kg should get an infusion solution of sodium phenylacetate and sodium benzoate (containing 5500 mg of each) as a loading dose over 90 to 120 minutes. The maintenance dose is given over 24 hours. The infusion should be diluted with 10% dextrose before administration with a dilution of 1:10. Arginine infusion should not exceed 150 mg/kg/h.
Patients with hyperammonemia may need to be monitored with EEG for seizure activity based on clinical status. The o-oxidation of valproic acid produces 2-propyl-4-pentoic acid, which inhibits carbamoyl phosphate synthetase I, 40 which in turn inhibits the enzymatic step just prior to the urea cycle, resulting in hyperammonemia (Figure 1) . Therefore, valproic acid is contraindicated in OTC deficiency. As seen in case 2, after the administration of valproic acid the levels of ammonia increased substantially.
These cases highlight the importance of understanding the variety of neurologic sequela associated with hyperammonemia, as a consequence of OTC deficiency, and the need for quickly treating intracranial hypertension that can develop in some of these critically ill patients. In our literature search, the mortality rate of late-onset presentation was 30% and most of the hyperammonemia crises were precipitated by an increased protein intake.
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